×
About 3,633 results

ALLMedicine™ Liposarcoma Center

Research & Reviews  1,085 results

A Contemporary Clinicopathologic Analysis of Primary Sarcomas of the Perinephric Soft T...
https://doi.org/10.1177/10668969221133356
International Journal of Surgical Pathology; Scheiderer AN, Bahrami A et. al.

Nov 29th, 2022 - A variety of primary malignant mesenchymal neoplasms can arise from the perinephric soft tissue and hilar vessels and potentially involve the kidney, mimicking primary renal tumors. A search was made at our institution for patients that underwent ...

Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinforma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682511
International Journal of Medical Sciences; Cui L, Tian X et. al.

Nov 29th, 2022 - Purpose: Retroperitoneal liposarcoma (RLPS) is a rare malignancy without effective treatment. Since current treatment for unresectable RLPS is unsatisfactory, immunotherapy and targeted therapy are urgently needed. Siglec-15 is a transmembrane pro...

What's the latest with investigational drugs for soft tissue sarcoma?
https://doi.org/10.1080/13543784.2022.2152324
Expert Opinion on Investigational Drugs; Cojocaru E, Napolitano A et. al.

Nov 26th, 2022 - Despite extensive research undertaken in the past 20-30 years, the treatment for soft tissue sarcoma (STS) has remained largely the same, with anthracycline-based chemotherapy remaining the first choice for treating advanced or metastatic STS. Thi...

MYC-Nonamplified Secondary Lymphatic-Type Angiosarcoma With Prominent Lymphocytic Infil...
https://doi.org/10.1097/DAD.0000000000002306
The American Journal of Dermatopathology; Krajisnik A, Balzer BL et. al.

Nov 18th, 2022 - Cutaneous angiosarcomas (AS) are uncommon and morphologically heterogeneous. Recently, a distinctive lymphatic-type AS with prominent lymphocytic infiltrate has been observed. Although conventional AS typically bear poor prognosis, lymphatic-type ...

A cryptic EWSR1::DDIT3 fusion in myxoid liposarcoma: Potential pitfalls with FISH and c...
https://doi.org/10.1002/gcc.23103
Genes, Chromosomes & Cancer; Ibstedt S, de Mattos CBR et. al.

Nov 16th, 2022 - Myxoid liposarcoma (MLS) is molecularly characterized by fusions involving the DDIT3 gene in chromosome band 12q13; the fusion partner is FUS in band 16p11 in 90-95% of the cases and EWSR1 in band 22q12 in the remaining 5-10%. Hence, molecular stu...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  94 results

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
https://clinicaltrials.gov/ct2/show/NCT05580588

Oct 14th, 2022 - Study SPH4336-US-01 is a multicenter, non-randomized, open-label Phase 2 study of SPH4336 with a safety lead-in in subjects with CDK4-positive liposarcomas (dedifferentiated or well-differentiated/dedifferentiated liposarcomas). SPH4336 is an oral...

Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
https://clinicaltrials.gov/ct2/show/NCT05218499

Oct 12th, 2022 - This study is open to people with a type of cancer called dedifferentiated liposarcoma. People with advanced liposarcoma aged 18 or older who are not receiving any other cancer treatment can participate. The purpose of this study is to compare a m...

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
https://clinicaltrials.gov/ct2/show/NCT04044768

Oct 10th, 2022 - This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1 and Cohort 2) or MRCLS (Cohort 1) .

SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
https://clinicaltrials.gov/ct2/show/NCT04967521

Oct 7th, 2022 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study of patients with advanced, recurrent and/or metastatic DDLS. Patients will be randomized 1:1 between abemaciclib and placebo and followed for disease progression. F...

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT02923778

Oct 6th, 2022 - PRIMARY OBJECTIVE: I. To estimate the pathologic complete necrosis rate (the number of patients with >= 95% necrosis divided by the number of evaluable patients) following preoperative treatment with talimogene laherparepvec (T-VEC) in combination...

see more →

News  234 results

Afamitresgene Autoleucel Induces Durable Clinical Response in Advanced Synovial Sarcoma Or Myxoid/Round Cell Liposarcoma
https://www.onclive.com/view/afamitresgene-autoleucel-induces-durable-clinical-response-in-advanced-synovial-sarcoma-or-myxoid-round-cell-liposarcoma

Nov 23rd, 2022 - Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), a novel T-cell therapy, produced good clinical response lasting more than 4 years in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS), according to findings f...

Camsirubicin Elicits Early Clinical Activity in Advanced Soft Tissue Sarcoma
https://www.onclive.com/view/camsirubicin-elicits-early-clinical-activity-in-advanced-soft-tissue-sarcoma

Nov 18th, 2022 - The doxorubicin analogue camsirubicin in combination with pegfilgrastim (Neulasta) produced encouraging clinical activity and safety in patients with advanced soft tissue sarcoma, according to data from a phase 1b trial (NCT05043649).1 Findings s...

Milademetan Shows Early Activity in MDM2-Amplified Advanced Solid Tumors
https://www.onclive.com/view/milademetan-shows-early-activity-in-mdm2-amplified-advanced-solid-tumors

Nov 10th, 2022 - Milademetan monotherapy demonstrated preliminary antitumor activity in patients with MDM2-amplified and p53 wild-type advanced solid tumors, according to data from the interim analysis of the phase 2 MANTRA-2 (RAIN-3202) trial (NCT05012397).1 As ...

Salarius Pauses Phase 1/2 Trial Investigating Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas Following Death
https://www.onclive.com/view/salarius-pauses-phase-1-2-trial-investigating-seclidemstat-in-ewing-sarcoma-and-fet-rearranged-sarcomas-following-death

Oct 19th, 2022 - Salarius Pharmaceuticals has voluntarily paused enrollment of new patients into a phase 1/2 trial (NCT03600649) investigating seclidemstat (SP-2577) in patients with Ewing sarcoma, sarcomas with FET-family translocations, and myxoid liposarcoma du...

ADP-A2M4CD8 Shows Promising Activity Across MAGE-A4+ Unresectable or Metastatic Tumor Types
https://www.onclive.com/view/adp-a2m4cd8-shows-promising-activity-across-mage-a4-unresectable-or-metastatic-tumor-types

Sep 10th, 2022 - An updated analysis of the phase 1 SURPASS trial (NCT04044859) showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease. The overall co...

see more →

Patient Education  26 results see all →